We studied DNA from 29 families with at least one member with ornithine carbamoyl transferase (OCT) deficiency and have found a mutation in the TaqI site within exon 5 of the OCT gene in a female presenting at the age of 21 months. Hybridisation with site specific oligonucleotides shows that the mutation is a C to T substitution resulting in a glutamine for arginine substitution at amino acid 109.
nine substitution at amino acid 109.
Ornithine carbamoyl transferase deficiency is an X linked disorder caused by mutation of the urea cycle enzyme ornithine carbamoyl transferase. Heterozygous females have very variable manifestations, some being virtually asymptomatic while others have severe protein intolerance and recurrent hyperammonaemia.' The reason for this variation is not known although it is usually assumed that it is a result of unequal X inactivation. A survey of mutations found in symptomatic females is needed to clarify the variation in clinical symptoms.
A number of mutations have been defined in males with OCT deficiency. These include deletions and point mutations.2-7 Of particular interest is the finding of several independent mutations having arisen at codon 109 within a TaqI restriction enzyme site.458 Mutations of C to T at this position in the coding strand change arginine to a stop codon45 and arginine to glutamine when the change occurs on the complementary DNA strand.5 Cell transfection studies confirmed that this latter change abolishes enzyme activity.8 The arginine to stop mutation has already been found in a mildly affected female patient4 and we now report the other, arginine to glutamine, change arising independently for a second time, in this case in an affected female. 
Materials and methods

CLINICAL DETAILS
The female proband is 3L years of age and presented at the age of 21 months with developmental delay (around the 9 to 10 month level) and poor growth (-3-62 SD). Increased urine glutamine and orotic acid confirmed OCT deficiency. On a low protein diet, sodium ben2oate, and arginine she has done well and her growth has caught up somewhat (now being only -1-96 SD). At 3j years of age her development is now borderline normal. There was no previous family history. Chromosomal analysis was not performed.
We Genomic DNA from the proband and her mother was amplified using primers specific for exon 5. TaqI digests of the amplified products showed two bands in the case of the proband (fig 2) , the expected digestion product of 121 bp from the unaffected X chromosome and an undigested fragment of 156 bp from the other X chromosome, confirming that the TaqI site has been mutated. Again the other digestion product of 35 bp was too small to detect.
DETECTION OF POINT MUTATION USING ALLELE SPECIFIC OLIGONUCLEOTIDE HYBRIDISATION
The amplified exon 5 products from the proband and her mother were tested for both predicted C to T mutations by hybridisation to radiolabelled oligonucleotides corresponding to the sense strand of the normal sequence, and to the sense strands of both mutations. The proband showed clear hybridisation to the normal oligonucleotide but with reduced intensity, as expected for a heterozygote, and to the oligonucleotide corresponding to the arginine to glutamine change (fig 3) . Her mother showed only hybridisation to the normal sequence. 
Discussion
The coding sequence for ornithine transcarbamylase contains four restriction enzyme sites for TaqI. Systematic studies in other diseases, both X linked and autosomal, show that the dinucleotide 5'CpG3 is particularly prone to mutation to 5'TpG". Examples have been found in the analysis of the factor IX gene in haemophilia B1011 and the phenylalanine hydroxylase gene in phenylketonuria."2 The reason for this is believed to be deamination of methyl C to form T, followed by repair of the resulting G.T mismatch to A.T. As the sequence is symmetrical this can happen in either strand resulting in C to T or G to A. A small proportion of CpG sequences will fall within TaqI sites (recognition site TCGA) and may be directly detectable on Southern blots. The mutation reported here falls within that class. However, the mutation within exon 1 is difficult to detect because of coincidence of band sizes. TaqI digestion of PCR amplified exon products provides a quick and clear screening method. We have examined 29 X chromosomes giving rise to OCT deficiency at four TaqI sites. We have only This report describes the second mutation found in a female patient. So far they both reproduce mutations found in severely affected males. Further reports are awaited in order to deduce whether the severity in females is connected in any way with the mutation or whether the proportion of X inactivation is the only critical factor.
As the patient's mother showed no alteration within her TaqI site in exon 5 it is very likely that the patient represents a new mutation. However, a small possibility of mosaicism within the germ cells of the mother remains2 and she could be offered prenatal diagnosis based on PCR amplification of exon 5 and TaqI digestion if required. 
